The same drug or dietary supplement can behave differently in different people. This is in part due to the difference in genome between individuals and it is also increasingly evident that this is caused, in part, by the different microbiome within individuals. If we are to achieve the health care objective of precision medicine then a greater understanding of this interaction is required.
- The microbiome has a profound impact on drug behavior in an individual
- This project allows for data pooling from different organizations an elegant and difficult pre-competitive activity
- A better understanding of the microbiome will lower barriers to R&D innovation
This project aims to develop a cross-industry microbiome expert group committed to addressing challenges around the influence of the microbiome on drugs and dietary supplements.
1) Establish a systematic, global and standardized map of the microbiome-derived metabolism and develop a database to include all the generated data so far on the bi-directional interaction between microbiome and drugs/dietary supplements.
2) Such data could be used as the foundation for developing various machine-learning algorithms that could help in predicting the influence of the microbiome and identify key enzymes which contribute to drug metabolism
3) create a common methodological framework for determining the bi-directional interaction between microbiome and drugs/dietary supplements, and for accurate data generation. This common framework could include validated methods and protocols, software, and computing infrastructure.
This project is relevant for pharma, nutraceutical organizations, and academic organizations looking at the effects of the microbiome.
Scientists involved in Microbiome Research, ADME/Tox Scientists, Bioinformaticians, Data Scientists, and AI/ML interested parties are welcome to participate. We are currently meeting monthly to continue to develop the project. Click here to express your interest.